Table 1. Demographic, gonadal state, fracture history and prevalence of low bone mass.
| Total | |
|---|---|
| Demographic | n=168 |
| Age /years (median (IQR)) | 45 (38-51) |
| Caucasian (%) | 163 (97) |
| MSM (%) | 162 (96) |
| BMI /kg/m2 (mean (95% CI)) | 25 (24.5-25.7) |
| BMI <18 (%) | 2 (1) |
| Current smoker (%) | 76 (45) |
| Alcohol >21units (%) | 52 (31) |
| IDU (%) | 3 (2) |
| History of hypogonadism (%) | 10 (6) |
| No regular exercise | 59 (35) |
|
| |
| HIV parameters | |
| Time since diagnosis/ months (median (IQR)) | 74 (34-149) |
| CDC stage A (%) | 99 (59) |
| B (%) | 39 (23) |
| C (%) | 30 (18) |
| VL/copies/mL (mean (95%CI)) | 14146 (5121-23171) |
| VL undetectable (<40 copies/mL (%)) | 118 (70) |
| CD4 count /cells/mm3 (median (IQR)) | 565 (415-735) |
| CD4 <200 cells/mm3 (%) | 6 (4) |
| cART exposure / weeks (median (IQR)) | 157 (4-522) |
| Current PI use (%) | 45 (27) |
| Current NNRTI use (%) | 71 (42) |
| Current TDF use (%) | 75 (45) |
|
| |
| Clinical hypogonadism (free testosterone <90pmol/l (%)) | 2 (1) |
|
| |
| BMD /g/cm2 (mean (95% CI)) | |
| Total hip | 0.95 (0.93-0.96) |
| Lumbar spine | 0.96 (0.94-0.98) |
|
| |
| T score < −2.5 or Z score < −2.0 (%) | 35 (21) |
Note: cART= combined anti-retroviral therapy; BMI= body mass index; IVDU= intravenous drug user; VL= viral load; PI= protease inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; TDF= tenofovir; BMD= bone mineral density